MedTrace Logo

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

NCT00260793 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-02-03

No results posted yet for this study

Summary

The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level.

Conditions

Interventions

DRUG

Ropinirole Hydrochloride

Sponsors & Collaborators

  • Colorado Neurology

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Agarwal, Pinky, M.D.

    lead INDIV

Principal Investigators

  • Pinky Agarwal, MD · Colorado Neurology, P.C.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00260793 on ClinicalTrials.gov